Reply

Annals of Surgery

Volumn 262, Issue 1, 2015, Pages e30-e31

  Torzilli, Guido ^a   Belghiti, Jacques ^b   Kokudo, Norihiro ^c   Takayama, Tadatoshi ^d   Capussotti, Lorenzo ^e   Nuzzo, Gennaro ^f   Vauthey, Jean Nicolas ^g   Choti, Michael A ^h   De Santibanes, Eduardo ⁱ   Donadon, Matteo ^a   Makuuchi, Masatoshi ^j  

^a UNIVERSITY OF MILAN   (Italy)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY OF TOKYO   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e MAURIZIANO HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF TEXAS   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^j JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BARCELONA CLINIC LIVER CANCER; CANCER STAGING; CANCER SURGERY; HUMAN; LETTER; LIVER CANCER; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SELECTION BIAS; SURGICAL APPROACH; TERTIARY CARE CENTER; CARCINOMA, HEPATOCELLULAR; CLINICAL PRACTICE; FEMALE; LIVER NEOPLASMS; LIVER RESECTION; MALE; STATISTICS AND NUMERICAL DATA;

CARCINOMA, HEPATOCELLULAR; FEMALE; GUIDELINE ADHERENCE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; PHYSICIAN'S PRACTICE PATTERNS; TERTIARY CARE CENTERS;

EID: 84938092031     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000382     Document Type: Letter

References (11)

1. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West Study Group. Ann Surg. 2013;257:929-937.
2. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
6. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.
7. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373: 614-616.
8. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
9. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255.
10. Rodriguez de Lope C, Tremosini S, Forner A, et al. Management of HCC. J Hepatol. 2012;55 (suppl 1):75-87.
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.